Core Insights - The company, Wuxi Xiangsheng Medical Technology Co., Ltd., is leveraging its deep technical expertise in ultrasound and innovation capabilities to navigate challenges, showing a stable upward trend in operational performance [1] - Xiangsheng Medical is actively embracing the "AI + Ultrasound" technology trend and is advancing its animal ultrasound business, aiming to deepen collaboration with global partners [1] Group 1: AI Ultrasound Innovations - As a leader in the AI ultrasound field, the company is establishing a comprehensive intelligent technology ecosystem driven by "ultrasound artificial intelligence + specialized models" [1] - The company has developed an intelligent standard framework covering "equipment research and development - image acquisition - diagnostic decision-making," creating a service network that integrates "precise screening - intelligent diagnosis - personalized rehabilitation" [1] Group 2: Veterinary Ultrasound Products - In 2025, the company successfully launched the SonoVet series of veterinary ultrasound products, which cater to various applications such as large animal reproduction and small animal abdominal and cardiovascular examinations [1] - These products are designed to meet diverse environmental needs in settings like farms, pet hospitals, mobile quarantine, and wildlife care, addressing pain points such as low image resolution and reliance on operator experience in traditional veterinary ultrasound [1] Group 3: Robotics and AI Integration - In addition to AI technology integration, the company has made significant breakthroughs in the robotics field, developing core technologies such as "visual recognition and analysis" and "precise control of robotic movement" [2] - The company has launched the "AI + Robot Scanning" series of solutions, with its flagship product, the "Breast Artificial Intelligence Ultrasound Robot," being the first to obtain a medical device testing report [2]

Core Viewpoint - The announcement details a significant equity change involving major shareholders of Wuxi Xiangsheng Medical Technology Co., Ltd., specifically regarding the reduction of shareholding by over 1% [3][4]. Group 1: Shareholder Information - The main shareholder, Mo Ruoli, along with her concerted parties, including Wuxi Xiangsheng Investment Co., Ltd., Wuxi Xiangding Investment Enterprise (Limited Partnership), Wuxi Xiangtong Investment Enterprise (Limited Partnership), and Shanghai Yude Technology Co., Ltd., is responsible for the disclosed information [2][3]. - The actual controllers of the company, Mo Shanjuo, Mo Ruoli, and Lu Jian, are identified as concerted actors [2]. Group 2: Equity Change Details - Mo Ruoli reduced her shareholding by 1,783,139 shares, representing 1.59% of the total share capital, between September 5, 2025, and November 6, 2025 [3]. - Following this reduction, the total shares held by Mo Ruoli and her concerted parties decreased from 80,723,956 shares to 78,940,817 shares, with the ownership percentage dropping from 71.99% to 70.40% [3]. Group 3: Additional Notes - This equity change is part of a previously disclosed share reduction plan by Mo Ruoli, as announced on August 15, 2025 [4]. - The reduction was executed through centralized bidding and block trading, and it does not trigger a mandatory tender offer [4]. - The equity change will not alter the controlling shareholder or actual controller of the company, nor will it significantly impact the company's governance structure or ongoing operations [5].

Core Points - The stock of Xiangsheng Medical (688358) closed at 34.92 yuan on November 7, 2025, down 0.6% from the previous trading day, with a total market capitalization of 3.915 billion yuan [1] - The stock opened at 35.1 yuan, reached a high of 35.22 yuan, and a low of 34.26 yuan, with a trading volume of 69.129 million yuan and a turnover rate of 1.78% [1] - The company announced that shareholder Mo Ruoli reduced his stake by 1,783,139 shares, accounting for 1.59% of the total share capital, between September 5 and November 6, 2025 [1] - Following this reduction, Mo Ruoli and his concerted parties' combined shareholding decreased from 71.99% to 70.40%, reaching a 1% integer threshold [1] - This change did not result in a change of the company's controlling shareholder or actual controller, did not trigger a mandatory bid, and did not violate previous commitments [1] Announcement Summary - The announcement regarding the change in equity of shareholders holding more than 5% was made by Xiangsheng Medical [2]

Group 1 - The core point of the article is that Xiangsheng Medical announced a significant reduction in shareholding by a major shareholder, Mo Ruoli, which has implications for the company's ownership structure and potential market perception [1] Group 2 - Mo Ruoli reduced her shareholding by 1,783,139 shares, representing 1.59% of the total share capital of Xiangsheng Medical [1] - Following this reduction, the total shares held by Mo Ruoli and her concerted parties decreased from 80,723,956 shares to 78,940,817 shares, resulting in a change in ownership percentage from 71.99% to 70.40% [1] - This change in equity ownership has triggered a notification as it touches the 1% threshold for reporting [1]

Core Insights - Xiangsheng Medical (688358.SH) has been officially included in the "pet economy" concept stocks, leveraging AI and other core technologies from human medical fields for animal healthcare applications [1][2] Group 1: Product Development and Market Entry - The SonoVet series of veterinary ultrasound products has been successfully launched and is now entering the global market, addressing multiple application scenarios such as large animal reproduction and small animal abdominal and cardiovascular examinations [2] - The company has established a comprehensive global sales network, with products exported to over 100 countries and regions, facilitating rapid entry into the pet healthcare market [2] Group 2: R&D Investment and Technological Advancements - Xiangsheng Medical emphasizes technology innovation as a core driver, with R&D investment reaching 56.57 million yuan, accounting for 16.48% of revenue in the first three quarters of 2025 [3] - The company is a leader in AI ultrasound technology, creating an intelligent standard framework that integrates "device development - image acquisition - diagnostic decision-making" [3] Group 3: AI and Robotics Integration - Significant breakthroughs have been made in robotics, with the development of core technologies such as "visual recognition and analysis" and "robotic motion precision control," leading to the launch of the "AI + robotics scanning" series solutions [4] - The establishment of a collaborative system integrating AI technology, high-definition probes, and ultrasound robots enhances the company's core competitiveness in high-precision diagnostics and intelligent operations [4] Group 4: Growth Potential - The optimization of revenue structure from high-end intelligent ultrasound products and the deep integration of AI and robotics are expected to enhance the company's profitability [4] - The veterinary ultrasound products represent a new growth point, potentially opening broader growth opportunities for the company [4]

Core Viewpoint - Xiangsheng Medical (688358.SH) announced a significant share reduction by shareholder Mo Ruoli, impacting the company's overall shareholding structure [1] Group 1: Shareholder Actions - Mo Ruoli reduced her holdings by 1.78 million shares from September 5, 2025, to November 6, 2025, representing 1.59% of the total share capital [1] - Following this reduction, the total shares held by Mo Ruoli and her concerted parties decreased from 80.72 million shares to 78.94 million shares, lowering their ownership percentage from 71.99% to 70.40% [1]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-042 无锡祥生医疗科技股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性公告 股东莫若理女士及其一致行动人无锡祥生投资有限公司、无锡祥鼎投资企业（有 限合伙）、无锡祥同投资企业（有限合伙）、上海御德科技有限公司保证向本公司提供的 信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | 控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | | | 重要内容提示： 权益变动方向 比例增加□ 比例减少 权益变动前合计比例 71.99% 权益变动后合计比例 70.40% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否 是否 ...

Core Viewpoint - Xiangsheng Medical (688358.SH) announced a significant share reduction by shareholder Mo Ruoli, impacting the company's overall shareholding structure [1] Group 1: Shareholder Actions - Mo Ruoli reduced her holdings by 1.78 million shares from September 5, 2025, to November 6, 2025, representing 1.59% of the total share capital [1] - Following this reduction, the total shares held by Mo Ruoli and her concerted parties decreased from 80.72 million shares to 78.94 million shares [1] - The shareholding percentage of Mo Ruoli and her concerted parties fell from 71.99% to 70.40%, marking a significant change in ownership structure [1]

Core Viewpoint - The announcement from Xiangsheng Medical indicates that shareholder Mo Ruoli has reduced his stake in the company, which does not affect the control or governance of the company [1] Shareholder Activity - Mo Ruoli reduced his holdings by 1.7831 million shares, representing 1.59% of the total share capital [1] - Following this reduction, Mo Ruoli and his concerted parties' shareholding decreased from 80.724 million shares to 78.9408 million shares, changing the ownership percentage from 71.99% to 70.40% [1] Impact on Company Control - The share reduction is part of a previously planned action and does not trigger a mandatory tender offer [1] - The reduction will not lead to changes in the controlling shareholder or actual controller, nor will it impact the company's governance and operations [1]

Summary of Key Points Core Viewpoint - On November 6, 2025, Xiangsheng Medical (688358) closed at 35.13 yuan, with a slight increase of 0.09% and a trading volume of 18,500 shares, resulting in a total transaction amount of 65.2013 million yuan [1][2]. Trading Information - On the same day, there was a significant block trade amounting to 21.3164 million yuan for Xiangsheng Medical [1][2]. - The net outflow of main funds was 364,700 yuan, accounting for 0.56% of the total transaction amount [1][2]. - The net inflow of speculative funds was 2.9077 million yuan, representing 4.46% of the total transaction amount [1][2]. - Retail investors experienced a net outflow of 2.543 million yuan, which is 3.9% of the total transaction amount [1][2].